Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

Arnold I. Freeman, Zichria Zakay-Rones, John M. Gomori, Eduard Linetsky, Linda Rasooly, Evgeniya Greenbaum, Shira Rozenman-Yair, Amos Panet, Eugene Libson, Charles S. Irving, Eithan Galun*, Tali Siegal

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

330 Scopus citations

Abstract

We undertook a Phase I/II trial in patients with apparent recurrent glioblastoma multiforme (GBM) based on imaging studies to determine the safety and tumor response of repetitive intravenous administration of NDV-HUJ, the oncolytic HUJ strain of Newcastle disease virus. The first part of the study utilized an accelerated intrapatient dose-escalation protocol with one-cycle dosage steps of 0.1, 0.32, 0.93, 5.9, and 11 billion infectious units (BIU) of NDV-HUJ (1 BIU = 1 × 109 EID50 50% egg infectious dose) followed by three cycles of 55 BIU. Virus was administered by intravenous infusion over 15 min. In the second part, patients received three cycles of 11 BIU. All patients without progressive disease were maintained with two doses of 11 BIU iv weekly. Eleven of the 14 enrolled patients (11-58 years, Karnofsky performance scale 50-90%) received treatment. Toxicity was minimal with Grade I/II constitutional fever being seen in 5 patients. Maximum tolerated dose was not achieved. Anti-NDV hemagglutinin antibodies appeared within 5-29 days. NDV-HUJ was recovered from blood, saliva, and urine samples and one tumor biopsy. One patient achieved a complete response. Intravenous NDV-HUJ is well tolerated. The findings of good tolerability and encouraging responses warrant the continued evaluation of NDV-HUJ in GBM, as well as other cancers.

Original languageAmerican English
Pages (from-to)221-228
Number of pages8
JournalMolecular Therapy
Volume13
Issue number1
DOIs
StatePublished - Jan 2006
Externally publishedYes

Keywords

  • Apoptosis
  • Brain cancer
  • Complete remission
  • Dose escalation
  • Glioblastoma
  • Intravenous
  • NDV-HUJ
  • Newcastle disease virus
  • Oncolytic virus
  • Phase I/II trial

Fingerprint

Dive into the research topics of 'Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme'. Together they form a unique fingerprint.

Cite this